天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁(yè)>CAS數(shù)據(jù)庫(kù)列表>204697-65-4

204697-65-4

中文名稱 N-[2-[5-氨基-1(S)-[4-(4-吡啶基)哌嗪-1-甲酰基]戊基氨基]-1(R)-(3,5-二溴-4-羥基芐基)-2-氧代乙基]-4-(2-氧代-1,2,3,4-四氫喹唑啉-3-基)哌啶-1-甲酰胺
英文名稱 BIBN 4096BS
CAS 204697-65-4
分子式 C38H47Br2N9O5
分子量 869.65
MOL 文件 204697-65-4.mol
更新日期 2025/01/07 08:45:04
204697-65-4 結(jié)構(gòu)式 204697-65-4 結(jié)構(gòu)式

基本信息

中文別名
N-[2-[5-氨基-1(S)-[4-(4-吡啶基)哌嗪-1-甲?;鵠戊基氨基]-1(R)-(3,5-二溴-4-羥基芐基)-2-氧代乙基]-4-(2-氧代-1,2,3,4-四氫喹唑啉-3-基)哌啶-1-甲酰胺
英文別名
BIBN-4096
Olcegepant
BIBN 4096BS
BIBN 4096BS API Olcegepant
1-[3,5-Dibromo-N-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]-D-tyrosyl-L-lysyl]-4-(4-pyridinyl)-piperazine
Piperazine, 1-[3,5-dibromo-N-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]-D-tyrosyl-L-lysyl]-4-(4-pyridinyl)-
N-[2-[5-Amino-1(S)-[4-(4-pyridinyl)piperazin-1-ylcarbonyl]pentylamino]-1(R)-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl]-4-(2-oxo-1,2,3,4-tetrahydroquinazolin-3-yl)piperidine-1-carboxamide
所屬類別
生物化工:激動(dòng)劑抑制劑

物理化學(xué)性質(zhì)

沸點(diǎn)1091.9±65.0 °C(Predicted)
密度1.497
儲(chǔ)存條件-20°C儲(chǔ)存
溶解度≥87 mg/mL in DMSO with gentle warming; insoluble in EtOH; insoluble in H2O
酸度系數(shù)(pKa)6.80±0.25(Predicted)
形態(tài)粉末
顏色White to off-white

常見(jiàn)問(wèn)題列表

生物活性
Olcegepant (BIBN-4096) 是有效和選擇性的降鈣素基因相關(guān)肽1 (CGRP1) 受體 拮抗劑,IC50 和 Ki 分別為0.03 nM,14.4 pM。
靶點(diǎn)

IC50: 0.03 nM (CGRP1)
Ki: 14.4 pM (hCGRP)

體外研究

Olcegepant possesses higher affinity for the human CGRP receptor than the endogenous ligand CGRP and 150-fold higher affinity compared to the peptidic antagonist CGRP8-37. Olcegepant reverses CGRP-mediated vasodilation in human cerebral vessels and inhibits neurogenic vasodilation in a surrogate animal model of migraine pathophysiology. Olcegepant (BIBN4096BS) is extremely potent at primate CGRP receptors exhibiting an affinity (K i ) for human CGRP receptors of 14.4±6.3 (n=4) pM. Several lines of evidence suggest that a calcitonin-gene related peptide (CGRP) receptor antagonist may serve as a novel abortive migraine treatment. Olcegepant (BIBN4096BS) exhibits competitive antagonism at the CGRP receptor present in SK-N-MC cells. Isolated human cerebral, coronary, and omental arteries are studied with a sensitive myograph technique. CGRP induces a concentration-dependent relaxation that is antagonized by Olcegepant in a competitive manner.

體內(nèi)研究

Olcegepant (BIBN4096BS) in doses between 1 and 30 μg/kg (i.v.) inhibits the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys. Pre-treatment with Olcegepant (900 μg/kg) inhibits the capsaicin-induced expression of Fos throughout the spinal trigeminal nucleus by 57%. In contrast, the expression of phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion is not changed by Olcegepant pre-treatment. Olcegepant (0.3 to 0.9 mg/kg, i.v.) markedly reduces mechanical allodynia in CCI-ION rats. Olcegepant (0.6 mg/kg, i.v.) significantly reduces the number of c-Fos immunolabeled cells in spinal nucleus of the trigeminal nerve and upregulation of ATF3 transcript (a marker of neuron injury) but not that of interleukin-6 in trigeminal ganglion of CCI-ION rats.

"204697-65-4" 相關(guān)產(chǎn)品信息
63-74-1